As of Nov 19, 2026, 2 of 2 active firms rate HIT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
HIT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.04
Range $-0.04 – $-0.04 · 1 analysts · +33% YoY
Next period, 1 analysts expect Health In Tech, Inc. Class A Common Stock to earn $-0.04 a share (range $-0.04 – $-0.04), versus $-0.03 a year earlier. Full-year consensus is $-0.13, growing to $0.10 the year after.
REVENUE · NEXT QUARTER
$7.4M
Range $7.2M – $7.5M · 1 analysts · -16% YoY
Revenue is expected to reach $7.4M (range $7.2M – $7.5M), -16.2% year-over-year. Full-year consensus is $29.7M, rising to $50.8M next year.
Top analysts covering Health In Tech, Inc. Class A Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on HIT.
#1
George Sutton
Craig-Hallum · Rank #216
Buy
$4.00+932.5% to target
Overall win rate
34%
+ Follow
#2
Allen Klee
Maxim Group · Rank #583
Buy
$3.00+674.4% to target
Overall win rate
18%
+ Follow
HIT stock forecast FAQ
What is HIT's average 12-month price target?+
The 2 active firms with a live target average $3.50 for Health In Tech, Inc. Class A Common Stock over the next 12 months, ranging from a $4.00 high to a $3.00 low, as of Nov 19, 2026.
Is HIT stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for HIT?+
The Street-high target is $4.00 (Craig-Hallum), and the Street-low is $3.00 (Maxim Group). The average of all 2 active-firm targets is $3.50.
How many active Wall Street firms cover HIT?+
2 active firms have a recognized rating on Health In Tech, Inc. Class A Common Stock as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering HIT?+
Among analysts who currently cover HIT, George Sutton of Craig-Hallum has the strongest overall Quantellect track record (Rank #216). Their current call is Buy with a $4.00 target.
What is Health In Tech, Inc. Class A Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.04 per share (range $-0.04 – $-0.04) across 1 analysts. Full-year EPS is projected at $-0.13, rising to $0.10 the following year.
How much revenue is Health In Tech, Inc. Class A Common Stock expected to report next quarter?+
Consensus revenue is $7.4M (range $7.2M – $7.5M). Full-year revenue is projected at $29.7M, growing to $50.8M next year.
Have analysts been upgrading or downgrading HIT lately?+
As of Nov 19, 2026, 2 of 2 active firms rate HIT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their HIT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.